Boothbay Fund Management, LLC Wave Life Sciences Ltd. Transaction History

Boothbay Fund Management, LLC

  • $3.27 Billion
  • Q4 2024

A detailed history of Boothbay Fund Management, LLC transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 29,400 shares of WVE stock, worth $287,826. This represents 0.01% of its overall portfolio holdings.

Number of Shares
29,400
Previous 174,112 83.11%
Holding current value
$287,826
Previous $1.43 Million 74.56%
% of portfolio
0.01%
Previous 0.04%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
SELL
$8.0 - $16.44 $901,176 - $1.85 Million
-112,647 Reduced 64.7%
61,465 $760,000
Q3 2024

Nov 14, 2024
BUY
$5.12 - $9.01 $33,566 - $59,069
6,556 Added 3.91%
174,112 $1.43 Million
Q2 2024

Aug 14, 2024
SELL
$4.38 - $6.48 $19,140 - $28,317
-4,370 Reduced 2.54%
167,556 $836,000
Q1 2024

May 15, 2024
BUY
$3.54 - $6.84 $608,618 - $1.18 Million
171,926 New
171,926 $1.06 Million
Q1 2023

May 15, 2023
BUY
$3.58 - $6.3 $25,296 - $44,515
7,066 Added 43.89%
23,166 $100,000
Q4 2022

Feb 14, 2023
BUY
$3.18 - $7.0 $51,198 - $112,700
16,100 New
16,100 $112,000
Q2 2022

Aug 15, 2022
SELL
$1.23 - $3.25 $106,206 - $280,627
-86,347 Reduced 75.56%
27,932 $91,000
Q3 2021

Nov 15, 2021
BUY
$4.89 - $7.12 $558,824 - $813,666
114,279 New
114,279 $560,000
Q3 2020

Nov 16, 2020
SELL
$8.49 - $19.54 $135,840 - $312,640
-16,000 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$7.44 - $11.29 $119,040 - $180,640
16,000 New
16,000 $167,000

Others Institutions Holding WVE

# of Institutions
192
Shares Held
122M
Call Options Held
430K
Put Options Held
330K
View Full List

About Wave Life Sciences Ltd.

WVE Quotes by TradingView
  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $850M
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email